MAPT and Alzheimer disease: Combined with hippocampal volumetry, fluorodeoxyglucose (FDG) PET, amyloid PET, decreased Aβ42, and increased tau or p-tau in CSF have been used in the National Institute for Aging-Alzheimer Association (NIA-AA) criteria to diagnose AD, to predict later onset of AD, and to differentiate AD from normal aging with MCI [1].